September 30, 2020
The Japan arm of Alnylam Pharmaceuticals said on September 29 that it has filed a new drug application in Japan for its RNA interference (RNAi) therapeutic givosiran sodium for the treatment of acute hepatic porphyrias (AHP). The regulatory submission rides...read more